410 related articles for article (PubMed ID: 16982776)
1. Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes.
Harrell JC; Dye WW; Allred DC; Jedlicka P; Spoelstra NS; Sartorius CA; Horwitz KB
Cancer Res; 2006 Sep; 66(18):9308-15. PubMed ID: 16982776
[TBL] [Abstract][Full Text] [Related]
2. Estrogen insensitivity in a model of estrogen receptor positive breast cancer lymph node metastasis.
Harrell JC; Dye WW; Harvell DM; Pinto M; Jedlicka P; Sartorius CA; Horwitz KB
Cancer Res; 2007 Nov; 67(21):10582-91. PubMed ID: 17975003
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneic expression of estrogen receptor between the primary tumor and the corresponding involved lymph nodes in patients with node-positive breast cancer and its implications in patient outcome.
Iguchi C; Nio Y; Itakura M
J Surg Oncol; 2003 Jun; 83(2):85-93. PubMed ID: 12772201
[TBL] [Abstract][Full Text] [Related]
4. A metastatic breast tumor cell line, GI-101A, is estrogen receptor positive and responsive to estrogen but resistant to tamoxifen.
Morrissey JJ; Raney S
Cell Biol Int; 1998; 22(6):413-9. PubMed ID: 10328849
[TBL] [Abstract][Full Text] [Related]
5. Progestins initiate a luminal to myoepithelial switch in estrogen-dependent human breast tumors without altering growth.
Sartorius CA; Harvell DM; Shen T; Horwitz KB
Cancer Res; 2005 Nov; 65(21):9779-88. PubMed ID: 16266999
[TBL] [Abstract][Full Text] [Related]
6. Expression of CD44 isoforms in human breast carcinoma xenografts is not influenced by the treatment of mice with cytostatics or (anti-)hormones.
Dehmel A; Becker M; Lemm M; Fichtner I
Anticancer Res; 1999; 19(3A):1977-87. PubMed ID: 10470143
[TBL] [Abstract][Full Text] [Related]
7. Increased sentinel lymph node lymphangiogenesis is associated with nonsentinel axillary lymph node involvement in breast cancer patients with a positive sentinel node.
Van den Eynden GG; Vandenberghe MK; van Dam PJ; Colpaert CG; van Dam P; Dirix LY; Vermeulen PB; Van Marck EA
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5391-7. PubMed ID: 17875768
[TBL] [Abstract][Full Text] [Related]
8. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.
Liang Y; Wu J; Stancel GM; Hyder SM
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):173-82. PubMed ID: 15860260
[TBL] [Abstract][Full Text] [Related]
9. 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer.
Wolf I; O'Kelly J; Rubinek T; Tong M; Nguyen A; Lin BT; Tai HH; Karlan BY; Koeffler HP
Cancer Res; 2006 Aug; 66(15):7818-23. PubMed ID: 16885386
[TBL] [Abstract][Full Text] [Related]
10. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
11. Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple metastases in immune deficient mice.
Jenkins DE; Hornig YS; Oei Y; Dusich J; Purchio T
Breast Cancer Res; 2005; 7(4):R444-54. PubMed ID: 15987449
[TBL] [Abstract][Full Text] [Related]
12. Five novel hormone-responsive cell lines derived from murine mammary ductal carcinomas: in vivo and in vitro effects of estrogens and progestins.
Lanari C; Lüthy I; Lamb CA; Fabris V; Pagano E; Helguero LA; Sanjuan N; Merani S; Molinolo AA
Cancer Res; 2001 Jan; 61(1):293-302. PubMed ID: 11196177
[TBL] [Abstract][Full Text] [Related]
13. 2-methoxyestradiol is an estrogen receptor agonist that supports tumor growth in murine xenograft models of breast cancer.
Sutherland TE; Schuliga M; Harris T; Eckhardt BL; Anderson RL; Quan L; Stewart AG
Clin Cancer Res; 2005 Mar; 11(5):1722-32. PubMed ID: 15755993
[TBL] [Abstract][Full Text] [Related]
14. [Loss of hormonal receptors expression from primary breast carcinoma to axillary lymph node metastases].
Cianga C; Cianga P; Cozma L; Diaconu C; Carasevici E
Rev Med Chir Soc Med Nat Iasi; 2003; 107(3):540-4. PubMed ID: 14756058
[TBL] [Abstract][Full Text] [Related]
15. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P
J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205
[TBL] [Abstract][Full Text] [Related]
16. Flaxseed alone or in combination with tamoxifen inhibits MCF-7 breast tumor growth in ovariectomized athymic mice with high circulating levels of estrogen.
Chen J; Power KA; Mann J; Cheng A; Thompson LU
Exp Biol Med (Maywood); 2007 Sep; 232(8):1071-80. PubMed ID: 17720953
[TBL] [Abstract][Full Text] [Related]
17. Steroid receptors and their role in the biology and control of breast cancer growth.
Cordera F; Jordan VC
Semin Oncol; 2006 Dec; 33(6):631-41. PubMed ID: 17145341
[TBL] [Abstract][Full Text] [Related]
18. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.
Wei B; Wang J; Bourne P; Yang Q; Hicks D; Bu H; Tang P
Hum Pathol; 2008 Dec; 39(12):1809-15. PubMed ID: 18715613
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
[TBL] [Abstract][Full Text] [Related]
20. Tumor and lymph node lymphangiogenesis--impact on cancer metastasis.
Tobler NE; Detmar M
J Leukoc Biol; 2006 Oct; 80(4):691-6. PubMed ID: 16793912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
